From the April 2021 issue of HealthCare Business News magazine
While all implants today are MR compatible, millions of people worldwide, including young people, have older devices that are not considered compatible.
The findings were published in Radiology: Cardiothoracic Imaging.
Fujifilm makes entry into surgical and fluoroscopy markets
FUJIFILM Medical Systems U.S.A. entered the surgical and fluoroscopy markets in November with the release of its Persona C Surgical C-Arm and Persona RF Premium System.
"As a longtime leader in diagnostic imaging, entering the radiographic fluoroscopy market with the innovative Persona C Surgical C-Arm and Persona RF PREMIUM System is a natural extension to our company and for our customers,” said Hidetoshi Izawa, vice president of modality solutions and clinical affairs at FUJIFILM Medical Systems U.S.A. Inc., in a statement.
The Persona C Surgical C-Arm allows for fast, precise positioning and advanced image quality for different diagnostic imaging and minimally invasive surgical procedures. The mobile C-arm system offers 21x21 cm or 30x30 cm amorphous silicon flat panel detection options for ultra-low-dose fluoroscopy and vascular imaging. It also has a removable grid with 81 cm of free space, and dedicated radiography mode for high-quality still imaging.
The Persona RF Premium System images skeletal, digestive, urinary, respiratory and reproductive systems in real time, as well as specific organs such as the heart, lungs and kidneys. It has a 17x17 DR detector and can be configured with an optional overhead tube crane and upright radiography Bucky.
Both solutions were shown at the 2020 virtual RSNA meeting.
Over 80% drop in SPECT-MPI had no impact on rate of abnormal findings
The University of Alabama Medical Center performed over 80% less SPECT myocardial perfusion imaging at the peak of the pandemic.
A retrospective study, however, performed by researchers at the University of Alabama at Birmingham found that the decrease did not create any shift in the rate of abnormal SPECT-MPI findings.
"We hypothesized that due to the highly restricted availability of testing, only high-yield patients will undergo SPECT-MPI, while those expected to be normal would be delayed," the authors wrote in January. "However, we did not find any statistically or clinically significant increase in the rate of abnormal SPECT-MPI or that of myocardial ischemia during this period."
Exams like SPECT-MPI were postponed in accordance with guidelines issued by both the American Society of Nuclear Cardiology and the Society of Nuclear Medicine and Molecular Imaging during the pandemic, leading to significant restrictions.
